

## Statement of Advice:

**adalimumab 40mg/0.4mL pre-filled syringe and pre-filled pen /  
adalimumab 40mg/0.4mL 40mg/0.8mL vial for paediatric use (Humira®)  
SMC No 1305/18**

**AbbVie Ltd**

8 December 2017

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation

**adalimumab (Humira®)** is not recommended for use within NHS Scotland.

**Indication under review:** Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman**  
**Scottish Medicines Consortium**